GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP ...

ViiV said the final analysis of HPTN 083 showed the superiority of long-acting cabotegravir, which was 66% more effective at preventing HIV when compared to daily oral Truvada tablets.

ViiV Healthcare understands this push-and-pull dynamic all too well and sought out to do something about it. “Both sides are waiting for the other person to initiate and take the lead in those deeper ...